CD274 and neoplasm: Therefore, immunotherapy with PD-1/PD-L1 inhibitors can enhance anti-tumor immunity, which is more suitable for patients in poor condition and with aggressive tumors and is important for the treatment of rapidly progressing mTNBC (Figure 2).